einstein (São Paulo). 11/Jul/2019;17(3):eRW4628.

Risk profile for antiangiogenic agent-related osteonecrosis of the jaws

Raquel D’Aquino Garcia Caminha ORCID logo , Gabriela Moura Chicrala ORCID logo , Luiz Alberto Valente Soares Júnior ORCID logo , Paulo Sérgio da Silva Santos ORCID logo

DOI: 10.31744/einstein_journal/2019RW4628


To establish the profile of patients who developed antiangiogenic agent-related osteonecrosis of the jaws, and identify the treatments currently used in dental management. We searched the PubMed®/Medline® and Scopus databases using the words “osteonecrosis AND antiangiogenic therapy”, with the following inclusion criteria: articles published in English, case reports, available online, and for an unlimited period. Of the 209 articles retrieved, 18 were selected, for a total of 19 case reports, since one article included two cases that met the inclusion criteria for this study. Medication-related osteonecrosis of the jaws is characterized by exposure of necrotic bone in the oral cavity that does not heal over a period of 8 weeks in patients with no previous history of radiation therapy. Antiangiogenic drugs are indicated in the treatment of certain tumors, since they stop the formation of new blood vessels, controlling tumor growth and the chance of metastasis. Dental prevention is essential in patients who will be put on antiangiogenic agents, to minimize the risk for osteonecrosis.

Risk profile for antiangiogenic agent-related osteonecrosis of the jaws